MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Nicholas J. Vogelzang, Daniel P. Petrylak et al.|Nature|2014Cited by 2.4k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Alain Ravaud, Ignacio Durán et al.|The Lancet|2017Cited by 1.4k
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Sanjeev Mariathasan, Zoe J. Assaf et al.|Nature|2021Cited by 603
Adhesion-Mediated Squamous Cell Carcinoma Survival through Ligand-Independent Activation of Epidermal Growth Factor ReceptorXiaodong Shen, Randall H. Kramer|American Journal Of Pathology|2004Cited by 125